A study of young Germans drinking beer showed higher heart rate as blood alcohol climbed, with no threshold. (ESCardio.org)
A growing case for serious, even fatal, off-target cardiac effects of immune checkpoint inhibitors used for cancer was reported in analysis of the World Health Organization database. (The Lancet)
“We’re probably going to be in the next century before we get parity,” said a researcher discussing findings that the proportion of female cardiologists rose only 2 percentage points from 2006 to 2015. (Cardiovascular Business)
After the ODYSSEY Outcomes trial showed cardiovascular outcome benefits to alirocumab (Praluent) at last week’s American College of Cardiology meeting in Orlando, FiercePharma reports that drug makers Sanofi and Regeneron expect to file for a label update to reflect that data by mid-2018 but probably couldn’t get it until early 2019.
The AliveCor KardiaBand on an Apple Watch distinguished atrial fibrillation from normal sinus rhythm with 84% specificity and 93% sensitivity and detected hyperkalemia with sensitivity in the 90% to 94% range with an artificial intelligence algorithm, in two studies reported at the ACC meeting. (MobiHealthNews)
A novel smartphone device measured blood pressure without a cuff with accuracy nearly as good as an upper arm cuff, according to a study in Science Translational Medicine reported by MedGadget.
Mixed signals and avoidance: Cardiology still too often is uncomfortable with palliative care discussions, Cardiovascular Business reports.
Are survivorship clinics for congenital heart disease patients sustainable? (Cardiovascular Business)
Neonates getting congenital heart defect surgery who had vocal fold motion impairment as a complication had more expensive, prolonged hospital stays but not worse outcomes in a large study. (JAMA Otolaryngology-Head & Neck Surgery)
The European Society of Cardiology released new guidelines on syncope.
A single center report of battery issues with the Nanostim leadless pacemaker was “worrisome.” (Circulation)
A pulse of light terminated nearly all arrhythmias among rats treated with optogenetic gene therapy in one proof-of-concept study. (ESCardio.org)